Skip to main content

Remote Job Finders (RJF)

EyePoint will halve workforce, end pivotal wet AMD trials early following second fail

EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to the asset’s potential in diabetic macular edema.

China tightens grip on biotech platform ownership but foreign licensing deals still okay

The new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in the form of licensing agreements.
Scroll to top